The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment

Hsiu Ying Hung, Yen Han Tseng, Chia Miao Liao, Sung Yi Chen, Ta Peng Wu, Yu Chin Lee, Yuh Min Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment. Materials and Methods. We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014. Results. Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P =.7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95% CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95% CI = 21.37-26; hazard ratio = 0.75; P =.399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone (P >.05). Conclusion. Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment.

Original languageEnglish
Pages (from-to)126-131
Number of pages6
JournalIntegrative Cancer Therapies
Volume16
Issue number1
DOIs
Publication statusPublished - Mar 1 2017
Externally publishedYes

Fingerprint

Herbal Medicine
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Therapeutics
Adenocarcinoma of lung
Disease-Free Survival
Patient Harm
Survival

Keywords

  • adenocarcinoma
  • Chinese herbal medicine
  • epidermal growth factor receptor
  • lung cancer
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Complementary and alternative medicine

Cite this

The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment. / Hung, Hsiu Ying; Tseng, Yen Han; Liao, Chia Miao; Chen, Sung Yi; Wu, Ta Peng; Lee, Yu Chin; Chen, Yuh Min.

In: Integrative Cancer Therapies, Vol. 16, No. 1, 01.03.2017, p. 126-131.

Research output: Contribution to journalArticle

@article{3bb6c4693dd548e48cd97b6d201c0852,
title = "The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment",
abstract = "Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment. Materials and Methods. We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014. Results. Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P =.7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95{\%} CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95{\%} CI = 21.37-26; hazard ratio = 0.75; P =.399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone (P >.05). Conclusion. Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment.",
keywords = "adenocarcinoma, Chinese herbal medicine, epidermal growth factor receptor, lung cancer, tyrosine kinase inhibitor",
author = "Hung, {Hsiu Ying} and Tseng, {Yen Han} and Liao, {Chia Miao} and Chen, {Sung Yi} and Wu, {Ta Peng} and Lee, {Yu Chin} and Chen, {Yuh Min}",
year = "2017",
month = "3",
day = "1",
doi = "10.1177/1534735416645181",
language = "English",
volume = "16",
pages = "126--131",
journal = "Integrative Cancer Therapies",
issn = "1534-7354",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment

AU - Hung, Hsiu Ying

AU - Tseng, Yen Han

AU - Liao, Chia Miao

AU - Chen, Sung Yi

AU - Wu, Ta Peng

AU - Lee, Yu Chin

AU - Chen, Yuh Min

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment. Materials and Methods. We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014. Results. Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P =.7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95% CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95% CI = 21.37-26; hazard ratio = 0.75; P =.399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone (P >.05). Conclusion. Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment.

AB - Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment. Materials and Methods. We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014. Results. Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P =.7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95% CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95% CI = 21.37-26; hazard ratio = 0.75; P =.399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone (P >.05). Conclusion. Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment.

KW - adenocarcinoma

KW - Chinese herbal medicine

KW - epidermal growth factor receptor

KW - lung cancer

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85019470094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019470094&partnerID=8YFLogxK

U2 - 10.1177/1534735416645181

DO - 10.1177/1534735416645181

M3 - Article

C2 - 27151582

AN - SCOPUS:85019470094

VL - 16

SP - 126

EP - 131

JO - Integrative Cancer Therapies

JF - Integrative Cancer Therapies

SN - 1534-7354

IS - 1

ER -